A Comparative Study between Lycorine and Galantamine Abilities to Interact with AMYLOID β and Reduce In Vitro Neurotoxicity

Galantamine is a natural alkaloid extracted from the Amaryllidaceae plants and is used as the active ingredient of a drug approved for the treatment of the early stages of Alzheimer’s disease. It mainly acts as an acetylcholinesterase (AChE) inhibitor, increasing concentrations of the acetylcholine neurotransmitter. Recent cellular studies have also shown the ability of galantamine to protect SH-SY5Y cell lines against amyloid-β (Aβ)-induced toxicity. Such investigations have supported and validated further in-depth studies for understanding the chemical and molecular features associated with galantamine-protective abilities. In addition to galantamine, other natural alkaloids are known to possess AChE inhibitory activity; among them lycorine has been extensively investigated for its antibacterial, anti-inflammatory and antitumoral activities as well. Despite its interesting biological properties, lycorine’s neuroprotective functions against Aβ-induced damages have not been explored so far. In this research study, the ability of galantamine and lycorine to suppress Aβ-induced in vitro neuronal toxicity was evaluated by investigating the chemical interactions of the two alkaloids with Aβ peptide. A multi-technique spectroscopic analysis and cellular cytotoxicity assays were applied to obtain new insights on these molecular associations. The comparison between the behaviors exhibited by the two alkaloids indicates that both compounds possess analogue abilities to interact with the amyloidogenic peptide and protect cells.

[1]  A. Gräslund,et al.  Big dynorphin is a neuroprotector scaffold against amyloid β-peptide aggregation and cell toxicity , 2022, Computational and Structural Biotechnology Journal.

[2]  B. Roques,et al.  Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules. , 2022, European journal of medicinal chemistry.

[3]  Shanshan Wang,et al.  Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease , 2022, Molecules.

[4]  I. Desgagné-Penix,et al.  Biotechnological Approaches to Optimize the Production of Amaryllidaceae Alkaloids , 2022, Biomolecules.

[5]  Zhi Yang,et al.  Lycorine and organ protection: Review of its potential effects and molecular mechanisms. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[6]  F. García-Cozar,et al.  Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives , 2022, Pharmaceutics.

[7]  A. Petruczynik,et al.  Determination of Anti-Alzheimer’s Disease Activity of Selected Plant Ingredients , 2022, Molecules.

[8]  Tian Xie,et al.  Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease , 2022, Ageing Research Reviews.

[9]  S. Becker,et al.  The calcium-free form of atorvastatin inhibits amyloid-β(1–42) aggregation in vitro , 2022, The Journal of biological chemistry.

[10]  A. Emwas,et al.  Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases , 2021, Pharmaceutics.

[11]  I. Doytchinova,et al.  The Amaryllidaceae alkaloids: an untapped source of acetylcholinesterase inhibitors , 2021, Phytochemistry Reviews.

[12]  J. Loureiro,et al.  Caffeic acid for the prevention and treatment of Alzheimer's disease: The effect of lipid membranes on the inhibition of aggregation and disruption of Aβ fibrils. , 2021, International journal of biological macromolecules.

[13]  A. Mamun,et al.  Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’s Disease , 2021, Molecules.

[14]  D. Valensin,et al.  Metal complexation mechanisms of polyphenols associated to Alzheimer's Disease. , 2021, Current medicinal chemistry.

[15]  L. Ilag,et al.  The amyloid-inhibiting NCAM-PrP peptide targets Aβ peptide aggregation in membrane-mimetic environments , 2021, iScience.

[16]  Filling the void for new Alzheimer’s disease therapy , 2021, Nature Aging.

[17]  A. Emwas,et al.  Living with the enemy: from protein-misfolding pathologies we know, to those we want to know , 2021, Ageing Research Reviews.

[18]  Jiaqing Yang,et al.  Lycorine hydrochloride suppresses stress‐induced premature cellular senescence by stabilizing the genome of human cells , 2021, Aging cell.

[19]  H. Molinari,et al.  Natural Compounds as Inhibitors of Aβ Peptide Aggregation: Chemical Requirements and Molecular Mechanisms , 2020, Frontiers in Neuroscience.

[20]  A. Cimmino,et al.  Advances in the Chemical and Biological Characterization of Amaryllidaceae Alkaloids and Natural Analogues Isolated in the Last Decade , 2020, Molecules.

[21]  M. Sabbagh,et al.  Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval , 2020, Alzheimer's Research & Therapy.

[22]  Athi N. Naganathan,et al.  The metal cofactor zinc and interacting membranes modulate SOD1 conformation-aggregation landscape in an in vitro ALS model , 2020, bioRxiv.

[23]  S. Lamponi,et al.  Novel Perspective on Alzheimer’s Disease Treatment: Rosmarinic Acid Molecular Interplay with Copper(II) and Amyloid β , 2020, Life.

[24]  A. Emwas,et al.  Using NMR spectroscopy to investigate the role played by copper in prion diseases , 2020, Neurological Sciences.

[25]  R. B. Giordani,et al.  Isoquinoline alkaloids reduce beta-amyloid peptide toxicity in Caenorhabditis elegans , 2020, Natural product research.

[26]  B. de Strooper,et al.  The β-Secretase BACE1 in Alzheimer’s Disease , 2020, Biological Psychiatry.

[27]  F. Kreutz,et al.  Genistein protects against amyloid‐beta‐induced toxicity in SH‐SY5Y cells by regulation of Akt and Tau phosphorylation , 2019, Phytotherapy research : PTR.

[28]  C. Dobson,et al.  Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease , 2019, Science Advances.

[29]  W. Bal,et al.  CuII Binding Properties of N-Truncated Aβ Peptides: In Search of Biological Function. , 2019, Inorganic chemistry.

[30]  P. Barbarino,et al.  THE STATE OF THE ART OF DEMENTIA RESEARCH: NEW FRONTIERS , 2019, Alzheimer's & Dementia.

[31]  W. O. Castillo,et al.  Caliphruria subedentata (Amaryllidaceae) decreases genotoxicity and cell death induced by β-amyloid peptide in SH-SY5Y cell line. , 2018, Mutation research. Genetic toxicology and environmental mutagenesis.

[32]  P. Faller,et al.  Ascorbate Oxidation by Cu(Amyloid-β) Complexes: Determination of the Intrinsic Rate as a Function of Alterations in the Peptide Sequence Revealing Key Residues for Reactive Oxygen Species Production. , 2018, Analytical chemistry.

[33]  S. Fan,et al.  Lycorine Suppresses Endplate-Chondrocyte Degeneration and Prevents Intervertebral Disc Degeneration by Inhibiting NF-κB Signalling Pathway , 2018, Cellular Physiology and Biochemistry.

[34]  H. Elmsellem,et al.  Antibacterial activity and virtual screening by molecular docking of lycorine from Pancratium foetidum Pom (Moroccan endemic Amaryllidaceae). , 2018, Microbial pathogenesis.

[35]  M. Tomás,et al.  Oxidative stress and the amyloid beta peptide in Alzheimer’s disease , 2017, Redox biology.

[36]  P. Alam,et al.  Vitamin B12 offers neuronal cell protection by inhibiting Aβ-42 amyloid fibrillation. , 2017, International journal of biological macromolecules.

[37]  Z. Yi,et al.  Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway , 2017, Science China Life Sciences.

[38]  W. Xiao,et al.  Phytochemical and biological investigations of Amaryllidaceae alkaloids: a review , 2017, Journal of Asian natural products research.

[39]  E. Sakamoto-Hojo,et al.  Galanthamine decreases genotoxicity and cell death induced by β-amyloid peptide in SH-SY5Y cell line. , 2016, Neurotoxicology.

[40]  Moriah L. Szpara,et al.  Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line. , 2016, Journal of visualized experiments : JoVE.

[41]  A. Bax,et al.  Monomeric Aβ1–40 and Aβ1–42 Peptides in Solution Adopt Very Similar Ramachandran Map Distributions That Closely Resemble Random Coil , 2016, Biochemistry.

[42]  Chunrong Qu,et al.  Biological and pharmacological activities of amaryllidaceae alkaloids , 2015 .

[43]  E. Osorio,et al.  Neuroprotective activity and acetylcholinesterase inhibition of five Amaryllidaceae species: a comparative study. , 2015, Life sciences.

[44]  E. Osorio,et al.  Alkaloid metabolite profiles by GC/MS and acetylcholinesterase inhibitory activities with binding-mode predictions of five Amaryllidaceae plants. , 2015, Journal of pharmaceutical and biomedical analysis.

[45]  M. Rosales-Hernández,et al.  In silico and in vitro studies to elucidate the role of Cu2+ and galanthamine as the limiting step in the amyloid beta (1–42) fibrillation process , 2013, Protein science : a publication of the Protein Society.

[46]  Mao Ye,et al.  Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition , 2012, Cancer Cell International.

[47]  J. H. Viles,et al.  Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc and iron in Alzheimer's, Parkinson's and prion diseases , 2012 .

[48]  P. Faller,et al.  Metal ions in neurodegenerative diseases , 2012 .

[49]  L. Messori,et al.  Metal compounds as inhibitors of β-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease , 2012 .

[50]  Marek Luczkowski,et al.  Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases) , 2012 .

[51]  D. Eisenberg,et al.  Toxic fibrillar oligomers of amyloid-β have cross-β structure , 2012, Proceedings of the National Academy of Sciences.

[52]  Yan Zhang,et al.  Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells , 2010, Experimental Gerontology.

[53]  J. Brennan,et al.  Structure-activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids. , 2010, Bioorganic & medicinal chemistry letters.

[54]  Manuela G. López,et al.  Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH‐SY5Y neuroblastoma cells , 2010, Journal of pineal research.

[55]  Dong-lai Wu,et al.  Galantamine inhibits calpain–calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells , 2010, Neuroscience Letters.

[56]  R. Kiss,et al.  Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. , 2009, Journal of medicinal chemistry.

[57]  B. Austen,et al.  Galantamine inhibits β-amyloid aggregation and cytotoxicity , 2009, Journal of the Neurological Sciences.

[58]  J. Ombetta,et al.  Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. , 2008, Neurotoxicology.

[59]  Milan Meloun,et al.  The thermodynamic dissociation constants of four non-steroidal anti-inflammatory drugs by the least-squares nonlinear regression of multiwavelength spectrophotometric pH-titration data. , 2007, Journal of pharmaceutical and biomedical analysis.

[60]  G. Perry,et al.  Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. , 2007, Biochemistry.

[61]  P. Faller,et al.  Redox Chemistry of Copper–Amyloid‐β: The Generation of Hydroxyl Radical in the Presence of Ascorbate is Linked to Redox‐Potentials and Aggregation State , 2007, Chembiochem : a European journal of chemical biology.

[62]  H. Kozłowski,et al.  Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). , 2006, Chemical reviews.

[63]  Manuela G. López,et al.  Unequal Neuroprotection Afforded by the Acetylcholinesterase Inhibitors Galantamine, Donepezil, and Rivastigmine in SH-SY5Y Neuroblastoma Cells: Role of Nicotinic Receptors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[64]  T. Carlomagno Ligand-target interactions: what can we learn from NMR? , 2005, Annual review of biophysics and biomolecular structure.

[65]  J. van Staden,et al.  Acetylcholinesterase Enzyme Inhibitory Effects of Amaryllidaceae Alkaloids , 2004, Planta medica.

[66]  C. Thompson FDA approves galantamine for Alzheimer's disease. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[67]  J. Miller FDA approves new protease inhibitor for HIV infection. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[68]  D. Walsh,et al.  An improved method of preparing the amyloid β-protein for fibrillogenesis and neurotoxicity experiments , 2000, Neurobiology of Aging.

[69]  A. J. Shaka,et al.  Multiple-pulse mixing sequences that selectively enhance chemical exchange or cross-relaxation peaks in high-resolution NMR spectra. , 1998, Journal of magnetic resonance.

[70]  K. M. Uchida,et al.  Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[71]  H. Brodaty,et al.  ALZHEIMER'S DISEASE INTERNATIONAL , 1997, International journal of geriatric psychiatry.

[72]  A. Nordberg,et al.  Muscarinic receptors in human SH-SY5Y neuroblastoma cell line: regulation by phorbol ester and retinoic acid-induced differentiation. , 1987, Brain research.

[73]  A. Ruusala,et al.  Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. , 1984, Cell differentiation.

[74]  A. Savitzky,et al.  Smoothing and Differentiation of Data by Simplified Least Squares Procedures. , 1964 .

[75]  J. Parodi,et al.  Ethanol reduces amyloid aggregation in vitro and prevents toxicity in cell lines. , 2013, Archives of medical research.

[76]  T. Mohamed,et al.  Investigating the binding interactions of galantamine with β-amyloid peptide. , 2013, Bioorganic & medicinal chemistry letters.

[77]  D. Langford,et al.  Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. , 2013, Methods in molecular biology.

[78]  L. Luo,et al.  Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge. , 2012, International immunopharmacology.

[79]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[80]  Christian Ludwig,et al.  Ligand based NMR methods for drug discovery. , 2009, Frontiers in bioscience.

[81]  Jiangli Yan,et al.  Transferred nuclear overhauser effect in nuclear magnetic resonance diffusion measurements of ligand-protein binding. , 2003, Analytical chemistry.

[82]  Tacrine granted marketing approval for Alzheimer's disease. , 1993, Clinical pharmacy.